[P1] A

[P1-013-A] Controlled, blinded and randomised field efficacy, and return-on-investment study of a next-generation porcine reproductive and respiratory syndrome virus type 2 (PRRSV2) modified live virus (MLV) vaccine

*PREBEN MORTENSEN¹, Nicolas Guerra¹, Han Smits¹ (1. Ceva Corporate Swine (France))

Keywords:

PRRS,PRRSV2,Persoporc,Next-generation MLV,NA,PRRSV-2,High return on investment,ROI